First 10 runs free
    Intelligence Feed event · Policy · 2026-10-26

    Microbiotica presents Phase 1b melanoma data combining MB097 with Keytruda

    Question

    Microbiotica presents Phase 1b melanoma data combining MB097 with Keytruda

    Direct answer

    Microbiotica presented Phase 1b clinical data from its MELODY-1 study at the ESMO Congress on October 26, 2026. The study evaluated MB097, a precision microbiome therapeutic, paired with Merck's pembrolizumab in advanced melanoma patients who had previously failed anti-PD-1 treatment. Trial readouts demonstrated viable safety profiles, robust microbiome engraftment, and renewed anti-tumor responses, offering a potential path to reverse checkpoint inhibitor resistance.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-26
    Published
    2026-10-26
    Revision
    1 · 2026-10-28

    Cite as: Market Ontology, “Microbiotica presents Phase 1b melanoma data combining MB097 with Keytruda”, revision 1, evidence through 2026-10-26. https://marketontology.com/market-events/2026-10-26/microbiotica-presents-phase-1b-melanoma-data-combining-mb097-with-keytruda-e3717f

    POLICY
    Microbiotica presents Phase 1b melanoma data combining MB097 with Keytruda
    Microbiotica presented Phase 1b clinical data from its MELODY-1 study at the ESMO Congress on October 26, 2026. The study evaluated MB097, a precision microbiome therapeutic, paired with Merck's pembrolizumab in advanced melanoma patients who had previously failed anti-PD-1 treatment. Trial readouts demonstrated viable safety profiles, robust microbiome engraftment, and renewed anti-tumor responses, offering a potential path to reverse checkpoint inhibitor resistance.
    MRK
    Impact
    58
    OCT 26
    SIG
    88%
    MRK
    Microbiotica presents Phase 1b melanoma data combining MB097 with Keytruda
    Microbiotica presented Phase 1b clinical data from its MELODY-1 study at the ESMO Congress on October 26, 2026. The study evaluated MB097, a precision microbiome therapeutic, paired with Merck's pembrolizumab in advanced melanoma patients who had previously failed anti-PD-1 treatment. Trial readouts demonstrated viable safety profiles, robust microbiome engraftment, and renewed anti-tumor responses, offering a potential path to reverse checkpoint inhibitor resistance.
    → Microbiome-mediated resensitization to anti-PD-1 therapy preserves long-term duration and clinical indication reach for Merck's pembrolizumab.
    Impact
    Microbiotica presented Phase 1b clinical data from its MELODY-1 study at the ESMO Congress on October 26, 2026. The study evaluated MB097, a precision microbiome therapeutic, paired with Merck's pembrolizumab in advanced melanoma patients who had previously failed anti-PD-1 treatment. Trial readouts demonstrated viable safety profiles, robust microbiome engraftment, and renewed anti-tumor responses, offering a potential path to reverse checkpoint inhibitor resistance.
    Affected
    MRK
    Transmission
    Microbiome-mediated resensitization to anti-PD-1 therapy preserves long-term duration and clinical indication reach for Merck's pembrolizumab.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    MRKindication duration expansion via checkpoint inhibitor combination efficacyUp1-3mMicrobiotica clinical release confirms pembrolizumab combination efficacy in refractory melanoma patients at ESMO 2026.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    MRKUpagreed140.61 2026-10-26+0.86%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    Find trades for this development

    Screen tradable expressions of this catalyst against your horizon and constraints. Nothing is submitted without your review.

    First 10 runs free

    First 10 runs free

    See today's live cards

    Public pages are published 24 hours after the product shows them. The product shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open live cards